🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are escalating globally, with estimates suggesting in excess of 82 million new cases each year. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This medication, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

According to findings detailed in a prominent scientific publication, zoliflodacin cured more than 90% of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which combines a dual-drug approach. The research involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in numerous developing nations.

Medical professionals on the front lines have voiced optimism. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is viewed as crucial to reduce the burden of the illness for individuals and to prevent the spread of untreatable gonorrhoea globally.